Apr. 9 at 5:00 PM
$INKT risk/reward feels pretty asymmetrical right now with P2 results at the end of next week, for a trial that's Investigator Initiated and feels like a cherry-on-top.
If it disappoints, well, the current focus is rather on pneumonia and ards, so the market would mostly shrug it off.
But if the response is good, my god, this is going to reprice savagely
